Abstract
Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast were involved in this study. The expressions of ER, PR, c-erbB-2 and p53 were immunostained in tumor tissues and serum p53 Abs were assayed using ELISA method. The correlations between p53 Abs and other clinical and biological markers were analyzed. Among 144 patients, 31 (21.5%) had positive p53 Abs, which was associated with several poor prognostic parameters including higher clinical stage (p = 0.0233), lymph nodes metastasis (p = 0.0033), negative ER expression (p = 0.0250) and positive c-erbB-2 status (p = 0.0227). There was also a strong correlation between p53 Abs and tumor p53 positivity (p < 0.0001). These results indicated that the presence of p53 Abs is probably triggered by the accumulation of tumor p53 protein, and it could be a useful marker to complement routine prognostic factors in breast cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
PL Chen YM Chen R Bookstein WH Lee (1990) ArticleTitleGenetic mechanisms of tumor suppression by the human p53 gene Science 250 1576–1580 Occurrence Handle2274789
M Hollstein D Sidransky B Vogelstein CC Harris (1991) ArticleTitlep53 mutations in human cancers Science 253 49–53 Occurrence Handle1905840
AM Davidoff JD Iglehart JR Marks (1992) ArticleTitleImmune response to p53 is dependent upon p53/HSP70 complexes in breast cancers Proc Natl Acad Sci USA 89 3439–3442 Occurrence Handle1373500
H Shimada Y Nabeya S Okazumi H Matsubara Y Funami T Shiratori H Hayashi A Takeda T Ochiai (2002) ArticleTitlePrognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma Surgery 132 41–47 Occurrence Handle10.1067/msy.2002.125307 Occurrence Handle12110794
M Bergqvist D Brattstrom K Lamberg P Hesselius J Wernlund A Larsson G Wagenius (2003) ArticleTitleThe presence of anti-p53 antibodies in sera prior to thoracic surgery in non-small cell lung cancer patients: its implications on tumor volume, nodal involvement, and survival Neoplasia 5 283–287 Occurrence Handle14511399
S Regele FD Vogl T Kohler R Kreienberg IB Runnebaum (2003) ArticleTitlep53 autoantibodies can be indicative of the development of breast cancer relapse Anticancer Res 23 761–764 Occurrence Handle12680180
M Cioffi MT Vietri P Gazzerro R Magnetta A D’Auria A Durante E Nola GA Puca AM Molinari (2001) ArticleTitleSerum anti-p53 antibodies in lung cancer: comparison with established tumor markers Lung Cancer 33 163–169 Occurrence Handle10.1016/S0169-5002(01)00201-X Occurrence Handle11551411
LV Crawford DC Pim RD Bulbrook (1982) ArticleTitleDetection of antibodies against the cellular protein p53 in sera from patients with breast cancer Int J Cancer 30 403–408 Occurrence Handle6292117
R Tang MC Ko JY Wang CR Changchien HH Chen JS Chen KC Hsu JM Chiang LL Hsieh (2001) ArticleTitleHumoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients Int J Cancer 94 859–863 Occurrence Handle10.1002/ijc.1541 Occurrence Handle11745489
M Bergqvist D Brattstrom A Larsson P Hesselius O Brodin G Wagenius (2004) ArticleTitleThe role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival BMC Cancer 4 66 Occurrence Handle10.1186/1471-2407-4-66 Occurrence Handle15367333
S Sangrajrang W Arpornwirat A Cheirsilpa P Thisuphakorn A Kalalak A Sornprom T Soussi (2003) ArticleTitleSerum p53 antibodies in correlation to other biological parameters of breast cancer Cancer Detect Prev 27 182–186 Occurrence Handle10.1016/S0361-090X(03)00066-7 Occurrence Handle12787724
A Leo ParticleDi S Chan M Paesmans K Friedrichs T Pinter V Cocquyt E Murray I Bodrogi E Walpole B Lesperance S Korec J Crown P Simmonds G Minckwitz ParticleVon JY Leroy V Durbecq J Isola M Aapro MJ Piccart D Larsimont (2004) ArticleTitleHER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Breast Cancer Res Treat 86 197–206 Occurrence Handle10.1023/B:BREA.0000036783.88387.47 Occurrence Handle15567936
S Meng D Tripathy S Shete R Ashfaq B Haley S Perkins P Beitsch A Khan D Euhus C Osborne E Frenkel S Hoover M Leitch E Clifford E Vitetta L Morrison D Herlyn LW Terstappen T Fleming T Fehm T Tucker N Lane J Wang J Uhr (2004) ArticleTitleHER-2 gene amplification can be acquired as breast cancer progresses Proc Natl Acad Sci USA 101 9393–9398 Occurrence Handle10.1073/pnas.0402993101 Occurrence Handle15194824
H Shimada T Ochiai F Nomura (2003) ArticleTitleJapan p53 Antibody Research Group: titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group Cancer 97 682–689 Occurrence Handle10.1002/cncr.11092 Occurrence Handle12548611
R Lubin B Schlichtholz JL Teillaud E Garay A Bussel CP Wild (1995) ArticleTitlep53 antibodies in patients with various types of cancer: assay, identification, and characterization Clin Cancer Res 1 1463–1469 Occurrence Handle9815945
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gao, Rj., Bao, Hz., Yang, Q. et al. The Presence of Serum Anti-p53 Antibodies from Patients with Invasive Ductal Carcinoma of Breast: Correlation to Other Clinical and Biological Parameters. Breast Cancer Res Treat 93, 111–115 (2005). https://doi.org/10.1007/s10549-005-4321-9
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-4321-9